



- (51) International Patent Classification:
A61K 48/00 (2006.01) A61K 39/02 (2006.01)
- (21) International Application Number:
PCT/US2012/047087
- (22) International Filing Date:
17 July 2012 (17.07.2012)
- (25) Filing Language:
English
- (26) Publication Language:
English
- (30) Priority Data:
61/509,028 18 July 2011 (18.07.2011) US
61/565,733 1 December 2011 (01.12.2011) US
- (71) Applicant (for all designated States except US): **MOUNT SINAI SCHOOL OF MEDICINE** [US/US]; One Gustave L. Levy Place, New York, NY 10029 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **BLANDER, Julie, Magarian** [US/US]; 65 Tokeneke Drive, North Haven, CT 06473 (US). **SANDER, Leif, Erik** [DE/DE]; Hagenauer Str. 10, 10435 Berlin (DE).
- (74) Agent: **LI, Z., Ying**; Ropes & Gray LLP, 1211 Avenue Of The Americas, New York, NY 10036 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

[Continued on next page]

(54) Title: BACTERIAL RNAS AS VACCINE ADJUVANTS

(57) Abstract: The invention features vaccine adjuvants comprising prokaryotic mRNA, and methods of vaccination using the adjuvants.




FIG. 4



DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

BACTERIAL RNAs AS VACCINE ADJUVANTS

Cross References to Other Applications

[0001] This application claims priority from U.S. Provisional Application 61/509,028, filed July 18, 2011, and U.S. Provisional Application 61/565,733, filed
5 December 1, 2011. The disclosures of those applications are incorporated by reference herein in their entirety.

Government Interest

[0002] This invention was supported in part by the U.S. Government under Grant No. AI080959A from the National Institutes of Health. The U.S. Government may
10 have certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing
15 pathogen, such as a microorganism in weakened or killed forms or an antigen derived from the microorganism. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy the pathogen that it later encounters. A successful immune response is characterized by, e.g., eradication of pathogens, tissue

repair, and short and long term immune memory. Vaccines can be prophylactic (e.g., to prevent or ameliorate the effects of a future infection by a pathogen), or therapeutic (e.g., vaccines against cancer or passive immunization against established infections, e.g., rabies). A vaccine often contains, or is administered with, an adjuvant. A

5 vaccine adjuvant is an agent that stimulates the immune system and increases the immune system's response to a vaccine. The adjuvant itself typically does not have any specific antigenicity.

[0004] Vaccination is the most effective public health measure to prevent infectious disease associated morbidity and mortality. Improving vaccines against bacterial
10 pathogens like *Mycobacterium tuberculosis* or enteropathogenic bacteria like *Shigella flexneri* would significantly lower public health costs that result from treating these infections. Generally, there are two types of microbe-based vaccine – live vaccines, which contain live pathogens, and dead vaccines, which contain killed pathogens.

[0005] Live vaccines have long been known to trigger far more vigorous immune
15 responses than their killed counterparts (Brockstedt *et al.*, *Nat Med* 11: 853-860 (2005); Cheers *et al.*, *Trends Microbiol* 4: 453-455 (1996); Detmer *et al.*, *Microb Cell Fact* 5: 23 (2006); Kawamura, *et al.*, *Infect. Immun.* 62: 4396-4403 (1994); Lauvau, *et al.*, *Science* 294: 1735-1739 (2001); von Koenig *et al.*, *Nature* 297: 233-234 (1982)). This has been attributed to the ability of live microorganisms to replicate and express
20 specialized virulence factors that facilitate invasion and infection of their hosts (Vance *et al.*, *Cell Host Microbe* 6: 10-21 (2009)). However, protective immunization can often be achieved with a single injection of live, but not dead, attenuated microorganisms stripped of their virulence factors. Pathogen associated molecular patterns (PAMPs), which serve to alert the immune system (Medzhitov, *Immunity* 30:
25 766-775 (2009); Takeuchi *et al.*, *Cell* 140: 805-820 (2010)) are present in both live and killed vaccines, suggesting that certain poorly characterized aspects of live microorganisms, not incorporated in dead vaccines, are particularly effective at inducing protective immunity.

[0006] Attenuated live vaccines are often superior to dead vaccine preparations, but
30 they still have the risk of causing a severe infection, especially in

immunocompromised individuals. Attenuated vaccine strains are usually genetically engineered pathogens. There is a significant public concern about the release of such strains. In addition, there is a risk of spontaneous reversion to virulence in attenuated organisms. These risks not only limit the use of attenuated live vaccines, but also
5 cause concern and impede compliance. Further, live vaccines are labile, requiring complicated measures for storing and shipping, and are more costly to handle than dead vaccines. Therefore, it would be advantageous to improve the efficacy of dead vaccines, to minimize the risks associated with immunization with live vaccines, as well as the costs of vaccine storage and handling. Such improvement would promote
10 public health and lower health care costs.

SUMMARY OF THE INVENTION

[0007] The present invention is based on our discovery that bacterial mRNA enhanced efficiency of dead vaccine preparations due to its newly discovered capacity to induce immune responses similar to those evoked by viable bacteria. Accordingly, an aspect of this invention is a vaccine composition comprising a nonviable immunogen (e.g., heat-killed bacterium) and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA (e.g., bacterial mRNA). In some embodiments, the prokaryotic mRNA may be delivered to the subject by using the immunogen as a cargo, i.e., the mRNA is contained within, or co-delivered with, the immunogen.

[0008] In some embodiments, the immunogen is an extracellular pathogen, or an intracellular pathogen. The immunogen can be a bacterium, and may be of a genus selected from a group consisting of *Escherichia*, *Streptococcus*, *Staphylococcus*, *Clostridium*, *Campylobacter*, *Enterococcus*, *Helicobacter*, *Moraxella*, *Acinetobacter*, *Shigella*, *Salmonella*, *Listeria*, *Legionella*, *Klebsiella*, *Pseudomonas*, *Brucella*, *Haemophilus*, *Bordetella*, *Borrelia*, *Bacteroides*, *Bacillus*, *Chlamydia*, *Neisseria*, *Francisella*, *Yersinia*, *Vibrio*, *Mycobacterium*, *Mycoplasma*, *Corynebacterium*, and *Rickettsia*.

[0009] In some embodiments, the invention features a tumor vaccine comprising a tumor antigen and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA.

In some embodiments, the tumor antigen is carried by a cell. In some embodiments, the invention features a tumor vaccine comprising an immunogenic peptide of microbial or mammalian origin and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA. In some embodiments, a prokaryotic mRNA is delivered to a subject by optionally using the cell as a cargo.

[0010] In some embodiments, the prokaryotic mRNA used in the adjuvants of this invention has a 3' stem-loop structure, has no 5' tri-phosphate group, has no 3' poly(A) tail, intramolecular base-pairing, and/or nucleotide modifications.

[0011] In some embodiments, the vaccine compositions of this invention further include a second adjuvant component, such as mineral oil in water emulsions (e.g., MF59, AS3, montanide), aluminum salts, CpG, monophosphory lipid A (a detoxified derivative of endotoxin from, e.g., the *Salmonella minnesota* Re595 strain; "MPLA"), QS21 (a saponin purified from *Quillaja saponaria* tree bark; its oil-in-water emulsion suspension is also known as AS02), lipopolysaccharides ("LPS"), peptidoglycans, and bacterial lipopeptides characterized by their ability to trigger Toll-like receptors residing on the plasma membrane or recycle through early endocytic compartments.

[0012] The invention further features an immunization kit comprising a vaccine composition comprising a nonviable immunogen and an adjuvant composition comprising prokaryotic mRNA. The invention also features an immunization kit comprising a vaccine composition comprising a tumor antigen and an adjuvant composition comprising prokaryotic mRNA. Various embodiments of the immunogen, tumor antigen, and prokaryotic mRNA are, for example, as those described above and further below.

[0013] The invention also features a method of eliciting an immune response in a subject, comprising administering to the subject the present composition, as well as a method of increasing the immune response to a killed vaccine in a subject, comprising administering the killed vaccine to the subject with an adjuvant comprising prokaryotic mRNA. The subject may be a human, a house pet, or a farm animal. The vaccination methods of this invention may protect the subject from developing an infectious disease; or protect the subject from developing a cancer, or treat a subject in

need of cancer immunotherapy. The vaccination methods of this invention may boost the immune response in a subject by increasing IL-1 β production, IFN- β production, increased IgG isotype levels, increased primary and secondary (recall or memory) T cell responses, and death of infected cells. Also included in this invention are methods of inducing IFN- β or IL-1 β production in immune cells comprising contacting the cells with the present composition, and methods of preparing a vaccine composition comprising mixing a target immunogen with prokaryotic mRNA.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1. Sensing bacterial viability induces IFN- β and activates the NLRP3 inflammasome in the absence of virulence factors. (a) IL-6, TNF- α , (b) IFN- β protein, mRNA (at 2h) in bone marrow derived macrophages (BMM) stimulated with medium (contr), 100 ng/ml Lipopolysaccharide (LPS), *ThyA* *E. coli* (EC), and heat-killed EC (HKEC), MOI=20. (c) IL-1 β (top), and *Il1b* mRNA (left y-axis), secreted IL-1 β (right y-axis) at indicated times (bottom). (d), (i) Caspase-1 immunoblots at 18h. Pyroptosis by lactate dehydrogenase (LDH) release (e), and Fluorescence-Activated Cell Sorter (FACS) analysis through detection of Annexin-V and 7-AAD staining (f) at 18h. IL-6 and IL-1 β in response to EC, viable or killed by different means (g, bone marrow derived DC (BMDC)), or viable or HK: EC, attenuated *Shigella* (BS103), *Salmonella* (Δ Spil/2), and *Listeria* (Δ Hly Δ FliC), or virulent *Salmonella* (SL1344) (h). (j) LDH, IL-1 β , and IL-6. All responses by BMM and measured at 24h unless indicated otherwise. #, 'Not detected'. Data represent ≥ 5 experiments. All bars represent mean $\pm$ s.e.m.

[0015] Figure 2. The TLR signalling adaptor TRIF controls 'viability-induced' responses. *Ifnb* transcription at 2h (a), IFN- β secretion at 24h (b), *Il1b* transcription at 2h (c), IL-1 β secretion (d), and LDH (e) 24h after phagocytosis of viable or HKEC. f. Caspase-1 immunoblot at 18h. a-f, data by BMM and represent ≥ 5 experiments. g. Gene microarray analysis of *wt* and *Trif*^{-/-} BMM treated with viable EC for 1, 3 or 6h (three biological replicates #1-3). Heat map of positive regulators/essential

components ('+') and negative regulators ('-') of inflammasomes. h. *Nlrp3* transcription at 1h in BMM. Serum IL-6 and IL-1 β 6h after injection of 1×10^9 viable EC or 5×10^9 HKEC (i), and splenic bacterial burdens 72h after injection of 1×10^8 non-auxotroph EC (j) into *wt*, *Trif*^{-/-}, *Asc*^{-/-} and *Nlrp3*^{-/-} mice. Each symbol represents one mouse. *, $p \leq 0.05$, **, $p \leq 0.01$, ***, $p \leq 0.001$. n.s., Not statistically significant. #, 'Not detected'. All bars represent mean $\pm$ s.e.m.

[0016] Figure 3. Bacterial RNA is a vita-PAMP that accesses cytosolic receptors during phagocytosis, and in the absence of virulence factors. a. LPS/Endotoxin, genomic DNA and total RNA in EC before and at indicated times after heat killing. b. Agarose gel electrophoresis of EC total RNA before and after heat killing at 60°C for 60min followed by 4°C incubation for indicated times. c,d. LDH, IL-1 β , IFN- β and IL-6 at 24h in response to viable and HKEC, or HKEC with 10 μ g/ml total EC RNA (HKEC+RNA). # in c,d, 'Not detected'. (a)-(d), data by BMM and represent ≥ 5 experiments. (e) Representative ratiometric epifluorescence imaging of BMM at 8h with Fdx alone (ctr 8h), Fdx and viable EC (EC 8h) or gentamicin-killed EC (Gent EC) (colour code indicates pH scale). Positive control: Ground silica (silica 1h). (f) Quantification of cytosolic Fdx (% of total Fdx/cell). Each dot represents % released Fdx/individual cell. Grey bars represent mean Fdx release. *, $p \leq 0.05$, **, $p \leq 0.01$, ***, $p \leq 0.001$. All bars represent mean $\pm$ s.e.m.

[0017] Figure 4. Bacterial messenger RNA constitutes an active vita-PAMP. (a)-(c) and (e)-(g). LDH, IL-1 β and IL-6 at 24h. (a) Total EC RNA treated with RNase I and RNase III, RNase III alone, or DNase prior to stimulation of BMDC. (b) BMM treated with viable or HKEC, or HKEC with 0.1 μ g/ml of different bacterial RNA; ribosomal (rRNA), messenger (mRNA), small (sRNA) or eukaryotic RNA (eukRNA). (c) BMDC responses. Gro-RNA; *in vitro* transcribed EC Gro-operon RNA. (d) Predicted secondary structure of Gro-RNA. Colour code indicates base pairing probability. (e) BMM treated with *in vitro* transcribed Gro-RNA or Gro dsRNA alone or with HKEC. (f) BMDC responses. Era-RNA and DNAPol-RNA; *in vitro* transcribed EC Era-GTPase and DNA-polymerase-III RNA, respectively. (g) BMM treated with different doses of unmodified (control), or modified Gro-RNA with

HKEC (5'cap, 5' m⁷G capping; CIP, calf intestinal phosphatase; 3'poly(A), 3'-polyadenylation). (a)-(g), #, 'not detected', all RNA at 10µg/ml except as noted, data represent ≥5 experiments. (h) Mice vaccinated and boosted twice with viable EC, HKEC or HKEC with 30µg total purified bacterial RNA (HKEC+RNA) (vaccination regimen in suppl. Fig. 22). Class-specific anti-*E. coli* antibody serum titers at 25 days. *, p≤0.05, **, p≤0.01, ***, p≤0.001. All bars represent mean ± s.e.m.

[0018] Figure 5. Various *in vitro* transcribed RNAs. The photo shows an agarose gel electrophoresis of DNA templates generated by PCR, using genomic *E. coli* DNA as a template. These templates contain T7-polymerase consensus sites in either one strand (GroEL/ES-ssRV1-RV4, DNA-pol III-ss, Era-ss) or both strands (GroEL/ES-ds), which allows *in vitro* transcription of RNA using recombinant T7 RNA polymerase. The images show predicted secondary structures of the RNA transcripts using the "RNA fold server" at the website rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi. The entire structure is shown for DNA pol III-ss and Era-ss. In addition, amplifications of the 3'-stem loop structures of GroEL/ES-ss RV1 (full length transcript of the GroEL/ES-operon), DNA pol III-ss, and Era-ss are shown. GroEL/ES-ss-RV2-4 are shorter transcripts, lacking the 3' end of the full length transcript.

[0019] Figure 6. Shortening of the GroEL/ES *in vitro* transcribed RNA or loss of the 3'-end structure results in diminished activity of the RNA. The photograph in the top panel shows a portion of the same DNA gel electrophoresis as Figure 5. BMDC were treated with live *E. coli* (EC) or heat killed *E. coli* (HKEC), or HKEC in combination with various *in vitro* transcribed RNAs. After 24 hours, pyroptotic cell death was measured by LDH-release (LDH, left panel). IL-1β (middle) and IL-6 (right panel) were measured by ELISA. HKEC + *in vitro* transcribed full length GroEL/ES RNA (GroEL/ES-ss-RV1) induce similar responses as EC, whereas addition of GroEL/ES transcripts that are shortened from the 3'-end (thus lacking the original 3'-stem loop structure) lack this activity.

[0020] Figure 7. Viable and heat killed *E. coli* induce NF-κB and MAPK activation. BMM were stimulated with viable or heat killed (HK) *ThyA*⁻ *E. coli* for the indicated

times. Cellular lysates were immunoblotted and probed for the indicated proteins. As a readout for NF- κ B activation, I κ B- α degradation was observed 10 minutes post stimulation with either viable or HK *ThyA*⁻ *E. coli*, and its re-synthesis restored detection at 40 minutes. MAPK activation was assessed by examining the phosphorylation of p38 (P-p38) which was detected beginning at 10 minutes after stimulation with either viable or HK *ThyA*⁻ *E. coli*.

[0021] Figure 8. Viability-induced responses are dose-dependent and not restricted to BMM. (a) BMM were stimulated with viable or heat killed (HK) *ThyA*⁻ *E. coli* at the indicated multiplicities of infection (MOI) for 24 hours. (b) BMDC, peritoneal macrophages (PM) and splenic DC (spl. DC) were incubated with LPS (100ng/ml), viable or heat killed (HK) *ThyA*⁻ *E. coli* for 24 hours. Lactate dehydrogenase (LDH), IL-1 β and IL-6 production were measured in the supernatants by ELISA. #; 'not detected', ND; not determined. All bars represent mean $\pm$ s.e.m.

[0022] Figure 9. Viable but not killed bacteria induce pyroptosis irrespective of mode of death. BMM were incubated with viable *ThyA*⁻ *E. coli* (EC) or *ThyA*⁻ *E. coli* killed by various means prior to addition to BMM. *ThyA*⁻ *E. coli* were killed by heat (HKEC), UV irradiation (UVEC), treatment with Gentamicin sulfate (Gent EC), or 70% Ethanol (C₂H₅OH EC). LDH release was measured in the supernatant 24 hours later. #; 'not detected'.

[0023] Figure 10. Different magnitude and kinetics of pyroptosis and IL-1 β production in response to viability versus virulence factors. BMM were incubated with the indicated bacteria for the indicated times, and pyroptosis (LDH release, left), IL-1 β (middle) and IL-6 production (right) were measured. SL1344 is a wild type (wt) strain of *Salmonella enterica* serovar Typhimurium; SL1344 Δ Spi1/2 is a mutant lacking the Salmonella pathogenicity island (SPI) 1 and SPI 2 T3SS. LDH and IL-1 β release were observed in response to both avirulent viable *ThyA*⁻ *E. coli* and SL1344 Δ Spi1/2 indicating a trigger other than virulence factors. On the other hand, wt *Salmonella enterica* serovar Typhimurium induced high levels of LDH and IL-1 β release within 3 hours, known to be T3SS dependent in this case (compare to levels with T3SS mutant

SL1344ΔSpi1/2). IL-6 levels were comparable in response to all bacteria except as expected for SL1344, where survival of the BMM was compromised.

[0024] Figure 11. Pyroptosis and IL-1 β secretion induced by viable avirulent *E. coli* are independent of the Nod-like receptor NLRC4. BMDC derived from wt or *Nlrc4*^{-/-} mice were incubated with viable or heat killed (HK) *ThyA*⁻ *E. coli*. Cell culture supernatants were harvested after 24 hours and pyroptosis was determined by measurement of LDH release. IL-1 β and IL-6 secretion was measured by ELISA. #; 'not detected'.

[0025] Figure 12. Pyroptosis induced by *E. coli* is mediated by caspase-1 and is independent of caspase-8. BMM were incubated with viable *ThyA*⁻ *E. coli* and the indicated caspase inhibitors. The specificities of inhibitors z-WEHD, z-IEDT and Q-VD-OPH to various caspases are indicated in parentheses. Pyroptosis was determined by measurement of LDH release at 24 hours.

[0026] Figure 13. IFN- β production induced by viable *E. coli* is dependent on TRIF-IRF3 signalling. (a) BMM derived from wt, *Myd88*^{-/-} or *Trif*^{-/-} mice were incubated with viable *ThyA*⁻ *E. coli* for the indicated times. Cell lysates were immunoblotted and probed for phosphorylated IRF3 (P-IRF3), total IRF3 and α -tubulin as indicated. (b) BMM derived from wt, *Trif*^{-/-} or *Irf3*^{-/-} mice were incubated with viable *ThyA*⁻ *E. coli* (EC) or heat killed (HK) *ThyA*⁻ *E. coli* (HKEC) or medium alone (ctr). IFN- β production was measured in supernatants after 24 hours by ELISA. #; 'not detected'.

[0027] Figure 14. *Salmonella enterica* serovar Typhimurium induces pyroptosis in macrophages independently of TLR signalling. BMM derived from wt, *Myd88*^{-/-}, *Trif*^{-/-} or *Myd88*^{-/-} x *Trif*^{-/-} mice were incubated with viable *ThyA*⁻ *E. coli* (EC), heat killed (HK) *ThyA*⁻ *E. coli* (HKEC) or viable *Salmonella enterica* serovar Typhimurium (SL1344) for 24 hours and LDH release was measured. #; 'not detected'.

[0028] Figure 15. Genome-wide transcriptional profile of wt and *Trif*^{-/-} BMM at various time points after phagocytosis of viable avirulent *E. coli*. BMM derived from wt or *Trif*^{-/-} mice were incubated with viable *ThyA*⁻ *E. coli* at a MOI of 20 for the indicated time points. RNA was extracted and subjected to transcriptional analysis by Affymetrix gene microarray. The results of three independent experiments is shown.

(a) IBMT q-value distribution comparing gene expression in wt and *Trif*^{-/-} BMM at steady state (far left '0h wt vs. *Trif*^{-/-}') and for wt and *Trif*^{-/-} BMM individually at 1, 3 and 6 hours after phagocytosis of *ThyA*⁻ *E. coli*. These results illustrate that there are no major differences in gene expression of wt and *Trif*^{-/-} BMM at steady state, and that both wt and *Trif*^{-/-} BMM rapidly induce a strong transcriptional response after uptake of *E. coli* as evidenced by a shift to low q-values in both genotypes. (b) Transcriptional profile of 9922 genes is shown in a heat map.

[0029] Figure 16. Expression of IFN-regulated genes and Rel/NF- κ B target genes in wt and *Trif*^{-/-} BMM at various time points after phagocytosis of viable avirulent *E. coli*. BMM derived from wt or *Trif*^{-/-} mice were incubated with viable *ThyA*⁻ *E. coli* at a MOI of 20 for the indicated time points. RNA was extracted and subjected to transcriptional analysis by Affymetrix gene microarray. The results of three independent experiments numbered 1, 2 and 3 are shown. Heat maps of (a) IFN-regulated genes and (b) Rel/NF- κ B target genes.

[0030] Figure 17. Pyroptosis and IL-1 β production induced by viable avirulent *E. coli* is independent of activation of the P2X7R, and TRIF is dispensable for ROS production. BMM derived from wt or *P2rx7*^{-/-} mice were incubated with the indicated stimuli for 24 hours and pyroptosis (a) and IL-1 β production (b) were measured. While viable *ThyA*⁻ *E. coli* induce significant release of LDH and IL-1 β in wt and *P2rx7*^{-/-} cells, LPS+ATP-induced pyroptosis and IL-1 β production are abrogated in *P2rx7*^{-/-} BMM. (c) BMM derived from wt or *Trif*^{-/-} mice were pulsed with the cell permeable ROS indicator H2DCFDA, washed and then incubated with the indicated stimuli for 1 hour and washed again. ROS production was measured by flow cytometry. #; 'not detected'.

[0031] Figure 18. TRIF deficiency strongly reduces IL-1 β production in response to wt and attenuated *Salmonella enterica* serovar Typhimurium *in vivo*. Wt and *Trif*^{-/-} mice were infected with 5x10⁸ cfu wt (SL1344) or mutant *Salmonella enterica* serovar Typhimurium lacking Salmonella pathogenicity island (SPI) 1 and 2 (SL Δ Spi1/2) by

intraperitoneal injection. Serum levels of IL-1 β and IL-6 after 6 hours were determined by ELISA.

[0032] Figure 19. Absolute quantifications of PAMP contents of viable and killed *E. coli*. *ThyA*⁻ *E. coli* were grown to log phase and either left untreated or subjected to heat killing. Heat killed *ThyA*⁻ *E. coli* were stored at 4°C for the times indicated and endotoxin/LPS, DNA and total RNA contents were measured. Endotoxin/LPS content was measured by Limulus Amebocyte Lysate (LAL) assay, DNA was extracted (DNeasy kit, Qiagen) and quantified using the optical density measured at 280/260nm, RNA was extracted (e.z.n.a. Bacterial RNA Kit (Omega Bio-Tek)) quantified using the optical density measured at 280/260nm.

[0033] Figure 20. Total RNA contents of viable and killed *E. coli*. *ThyA*⁻ *E. coli* were grown to log phase and either left untreated or subjected to killing by the indicated method (HK; heat killing at 60°C for 60 minutes, Gent; Gentamicin sulfate treatment for 12 hours, UV; UV irradiation for 10 minutes, C₂H₅OH; 70% Ethanol treatment for 10 minutes followed by washing). Total RNA was extracted from 5x10⁸ bacteria in each case and visualized by 1% agarose gel electrophoresis.

[0034] Figure 21. Paraformaldehyde fixation preserves the bacterial RNA content and restores cellular responses. (a) *ThyA*⁻ *E. coli* were grown to log phase and either left untreated or subjected to heat killing (HK) or paraformaldehyde (PFA) fixation. Total RNA yield extracted from 5x10⁸ bacteria respectively was measured. (b) BMM were stimulated with viable, HK or PFA fixed *ThyA*⁻ *E. coli* for 24 hours. LDH (left) and IL-1 β (middle) and IL-6 (right) release were measured in the supernatants. #; 'not detected'.

[0035] Figure 22. Bacterial RNA alone or in combination with LPS is insufficient to induce inflammasome activation unless delivered directly into the cytosol. BMM were stimulated with total RNA isolated from *ThyA*⁻ *E. coli* for 24 hours at the indicated concentrations in the presence or absence of LPS and/or Lipofectamine (LF) transfection reagent (Invitrogen). Lipofectamine treatment encapsulates nucleic acids allowing them to cross the plasma membrane and to be released into the cytosol. A combination of LPS and RNA was used to mimic an *E. coli* derived PAMP and RNA.

LDH (top) and IL-1 β release (bottom) were measured in the supernatants. Note that the LDH and IL-1 β levels detected after LF+LPS+RNA treatment are lower than after HK *E. coli* + RNA treatment (Fig. 3c). LPS alone had no effect (data not shown). #; 'not detected'.

5 [0036] Figure 23. Phagocytosis of *E. coli* induces low level leakage of phagolysosomal contents into the cytosol of BMM. (a) Epifluorescence images of fluorescein dextran (Fdx) loaded, permeabilized BMMs were taken at fixed pHs. The ex. 485 nm:ex. 440 ratios were measured and used to generate pH calibration curves (4 parameter sigmoid curve calculated by non-linear regression in sigmaplot). Error bars
10 indicate standard deviations. (b) Mean Fdx released into pH neutral compartments relative to total cellular Fdx content was measured in BMMs at the indicated time points after incubation with either medium (Fdx) or viable (Fdx+EC) or gentamicin killed *ThyA*⁻ *E. coli* (Fdx+Gent EC) and expressed as percent Fdx release. Mean was calculated from data shown in Fig. 3f.

15 [0037] Figure 24. Messenger RNA (mRNA), but not ribosomal RNA (rRNA), is sufficient to restore inflammasome activation and IFN- β production in response to heat killed *E. coli*. (a) Total RNA was extracted from *ThyA*⁻ *E. coli*, fractionated into ribosomal rRNA, mRNA, and small RNA (sRNA), and subsequently visualized by 1% agarose gel electrophoresis. (b) BMM were incubated with heat killed (HK) *ThyA*⁻ *E. coli* in combination with the indicated doses of purified *E. coli* rRNA (left) or mRNA
20 (right). At 24 hours, pyroptosis was measured as LDH release. (c) BMM were incubated with HK *ThyA*⁻ *E. coli* in combination with 0.1 μ g/ml of the indicated RNA species isolated from *ThyA*⁻ *E. coli*. At 24 hours, pyroptosis was measured as LDH release and IL-1 β , IFN- β and IL-6 production were measured by ELISA. #; 'not detected'.
25

[0038] Figure 25. *In vitro* transcribed *E. coli* Gro-mRNA activates the inflammasome only in combination with heat killed *E. coli* and independently of aberrant transcripts. (a) 1% Agarose gel electrophoresis of PCR amplified full-length *E. coli* Gro-operon, using genomic *E. coli* DNA as template, shows a product of 2.1kb.
30 A T7-promotor sequence was introduced in either the sense strand (Gro FWT7, RV) or

both the sense and the anti-sense strand (FWT7, RVT7). (b) In vitro transcription of the PCR product Gro (FWT7, RV) using T7 polymerase yielded Gro-RNA that migrates at 0.95kb, indicating extensive secondary structures resulting in shorter RNA fragments due to base pairing. In vitro transcription of Gro (FWT7, RVT7) yields two complementary strands that hybridize, thus do not allow formation of extensive secondary structures and therefore migrate at the predicted size of 2.1kb. (c) BMM were incubated with heat killed (HK) *ThyA*⁻ *E. coli* and the indicated stimuli for 24 hours. Cell lysates were immunoblotted and probed for caspase-1 p10. (d) BMM were incubated with increasing concentrations of Gro-RNA or Gro-dsRNA alone or in combination with HK *ThyA*⁻ *E. coli* for 24 hours, and pyroptosis and IL-1 β production (Fig. 4i) were measured. (e) In order to rule out the possibility that aberrant transcripts with 3' extensions, frequently observed with T7 polymerase (Cazenave and Uhlenbeck, *Proc Natl Acad Sci U S A* 91:6972-6976 (1994)), were responsible for the activity of in vitro transcribed Gro-RNA, we excised and purified Gro-RNA from agarose gels and added it to BMM (at 10 μ g/ml) in combination with HK *E. coli*, and measured IL-1 β and IL-6 production after 24 hours by ELISA. We compared the activity of gel-extracted Gro-RNA (gel extr.) to regular Gro-RNA and to purified total *E. coli* RNA. #: 'not detected'.

[0039] Figure 26. Dephosphorylation of total *E. coli* RNA or purified *E. coli* mRNA does not affect inflammasome activation. (a) Total RNA was isolated from viable *ThyA*⁻ *E. coli* and BMM were stimulated with heat killed (HK) *ThyA*⁻ *E. coli* in combination with *E. coli* RNA (HKEC+RNA) or dephosphorylated (CIP treated) *E. coli* RNA (HKEC+RNA/CIP) at the indicated concentrations. (b) BMM were stimulated with HK *ThyA*⁻ *E. coli* (HKEC), HK *ThyA*⁻ *E. coli* and 0.1 μ g/ml of purified *E. coli* mRNA (HKEC+mRNA), HK *ThyA*⁻ *E. coli* and 0.1 μ g/ml of purified *E. coli* mRNA pre-treated with RNase III (HKEC+mRNA/RNaseIII), or HK *ThyA*⁻ *E. coli* and 0.1 μ g/ml of dephosphorylated *E. coli* mRNA (HKEC+mRNA/CIP). After 24 hours, pyroptosis (LDH), IL-1 β and IL-6 release were measured. #: 'not detected'. (c, d) Mouse embryonic fibroblasts derived from RIG-I^{+/+} or RIG-I^{-/-} mice were

transfected with in vitro transcribed Gro-RNA at 0.1µg/ml (c) or 1µg/ml (d). IFN-β gene expression 2 hours after transfection was measured by quantitative real time RT-PCR.

[0040] Figure 27. Polyadenylation of *E. coli* mRNA impairs inflammasome activation. mRNA was isolated from total *E. coli* RNA and 3' polyadenylated using *E. coli* poly(A) polymerase (EPAP) (mRNA+poly(A)) or left untreated (mRNA). BMM were then stimulated with heat killed (HK) *ThyA*⁻ *E. coli* alone or in combination with the indicated concentrations of untreated or polyadenylated *E. coli* mRNA. After 24 hours, pyroptosis (LDH release), IL-1β and IL-6 production were measured. #: "not detected."

[0041] Figure 28. Schematic of vaccination regimen used for immunizations shown in Fig. 4h.

[0042] Figure 29. Poly (I:C) RNA does not restore the immune responses associated with bacterial viability. BMDC were treated with viable *E. coli*, or HKEC, HKEC with 10µg/ml of total bacterial RNA, HKEC with 3µg/ml low molecular weight (LMW) poly(I:C), HKEC with 3µg/ml high molecular weight (HMW) poly(I:C), or HKEC with both LMW and HMW poly(I:C). IL-1β and TNF-α levels were measured by ELISA at 24 hours by ELISA, and are reported in ng/ml (a and b). LDH release from BMDC was measured at 24 hours by ELISA as a percent of maximal release as determined by total cell lysis (b). TNF-α ELISA optical density (O.D.) values measured by a spectrophotometer at 495nm wavelength are also shown (b).

DETAILED DESCRIPTION OF THE INVENTION

[0043] The present invention is based on our discovery of the molecular mechanisms underlying the different efficacies of live and dead vaccines. Our studies described below show for the first time that antigen-presenting cells can sense microbial viability through recognition of prokaryotic mRNA. Optimal activation of antigen-presenting cells is a basic prerequisite for the generation of protective adaptive immunity, which is the ultimate goal of vaccination. We have discovered that addition of purified bacterial mRNA to heat inactivated bacteria elicited the same immune response in

antigen-presenting cells as did viable bacteria. By prokaryotic RNA (e.g., bacterial mRNA) as vaccine adjuvants, we have developed improved dead vaccines that combine their higher safety profile with the efficacies of live vaccines.

[0044] Most adjuvants in existing vaccination technologies are unspecific and trigger a broad range of immune responses. It is not entirely clear which responses are actually required to generate robust immunity, and which responses may even inhibit the generation of immunological memory. So far, mostly empiric data serve as the basis for adjuvant use. Due to their unspecific nature, many vaccine adjuvants are known to cause significant local and systemic side effects.

[0045] We have discovered that prokaryotic RNA, e.g., bacterial mRNA, significantly enhances the desired immune response and thus can be used as an adjuvant in a vaccine composition. The enhanced immune response is specific to the target immunogen in the vaccine composition, rather than nonspecific as often seen with conventional adjuvants. In other words, prokaryotic RNA can be used as an adjuvant to augment the effects of a vaccine with fewer side effects. Specifically, the invention features the use of purified prokaryotic RNA (e.g., bacterial mRNA or similar synthetic RNA) as vaccine adjuvant to mimic infection with live microbes and thereby improve dead vaccine efficiency and adjuvant specificity. The improved dead vaccines of this invention avoid the risks associated with handling and administration of live vaccines, especially in infants, elderly and immunocompromised patients.

Prokaryotic RNA Adjuvants

[0046] The adjuvant of the present invention comprises an effective amount of prokaryotic RNA, i.e., an amount of prokaryotic RNA sufficient to stimulate the anti-target immune response to a desired level, such that protective immunity is generated in a recipient. As used herein, "prokaryotic RNA" refers to RNA isolated from prokaryotic microorganisms such as archaea and bacteria, and to RNA having structural features characteristics of RNA obtained from prokaryotic microorganisms. In the latter case, the RNA may or may not have significant sequence homology to naturally occurring prokaryotic RNA, despite having the same structural features. The immune-enhancing property of the prokaryotic RNA is not sequence-specific. That is,

a prokaryotic RNA would have immune-enhancing effects, regardless of its particular nucleotide composition, as long as the requisite structural features are present.

[0047] In some preferred embodiments, the prokaryotic RNA in the adjuvant comprises bacterial messenger RNA (mRNA) and/or RNA having structural features of bacterial mRNA. Such structural features include, for example, absence of 3' polyadenylation (poly(A) tail), presence of a double-stranded secondary structure such as a 3' stem-loop structure, lack of eukaryotic modifications (e.g., certain nucleoside modifications), lack of 7m⁷G capping at the 5' end, and special nucleoside modifications that exist in bacterial mRNA but not in other bacterial RNAs or in eukaryotic RNAs. These structural features can be introduced to the RNA molecule during synthesis. Further structure features may also be introduced to enhance the RNA molecules' adjuvant and immunostimulatory activities. For example, unique conformations may be important in imparting immunogenicity on an RNA molecule, and thus, modifications can be made in the synthetic RNA molecule such that the RNA molecule assumes a linear noncircular conformation of bacterial mRNA.

[0048] In some embodiments, the prokaryotic RNA has a length ranging, for example, from about 50 nucleotides to about 2000 nucleotides, e.g., from about 800 nucleotides to about 2000 nucleotides. In some embodiments, the RNA has a length ranging from about 2000 nucleotides to more than 8000 nucleotides; for example, the mRNA encoding the *Clostridium difficile* toxin A subunit is 8130 nucleotides long. In some embodiments, the prokaryotic RNA does not have any 5' triphosphate group.

[0049] In some embodiments, the prokaryotic RNA is modified to increase stability. Exemplary stabilized RNA molecules include, *inter alia*, RNA molecules having a CpG, C*pG, C*pG*, or CpG* sequence where C* may be 2'-deoxythymidine, 1-(2'-deoxy-.beta.-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2'-dideoxy-5-halocytosine, 2'-dideoxy-5-nitrocytosine, arabinocytidine, 2'-deoxy-2'-substituted arabinocytidine, 2'-O-substituted arabinocytidine, 2'-deoxy-5-hydroxycytidine, 2'-deoxy-N4-alkyl-cytidine, 2'-deoxy-4-thiouridine, or other non-natural pyrimidine nucleosides, G* is 2'-deoxy-7-deazaguanosine, 2'-deoxy-6-thioguanosine, arabinoguanosine, 2'-deoxy-2' substituted-arabinoguanosine, 2'-O-substituted-

arabinoguanosine, 2'-deoxyinosine, or another non-natural purine nucleoside, and p may be an internucleoside linkage such as phosphodiester, and phosphorothioate (see, e.g., U.S. Patent 8,008,267 to Kandimalla et al.); and RNA molecules having protected 3' and/or 5' ends (see, e.g., U.S. Patent Application Publication No. 2008/0171712 by
5 Kandimalla et al.).

[0050] The prokaryotic RNA useful in this invention can be isolated from, e.g., bacterial cells by well known methods. For example, bacteria cells are homogenized or disrupted using a combination of denaturants and RNase inhibitors, including, e.g., TRIzol® (Life Technologies). This step is followed by the addition of chloroform to
10 the lysate, and the mixture is separated into three phases by centrifugation. The RNA is then precipitated from the aqueous phase with isopropanol. Alternatively, whole RNA can be extracted using silica-gel column based approaches. Messenger RNA can be purified by negative selection, for example, by removal of rRNA using immobilized rRNA-specific probes (e.g., immobilized on magnetic bead), followed by
15 chromatography to exclude non-rRNA species of smaller size (e.g., tRNA). RNA can be stabilized by various commercially available stabilizers, e.g., RNAlater® (Life Technologies), an aqueous storage reagent that stabilizes and protects RNA, and various widely available RNase inhibitors.

[0051] Cellular sources for the prokaryotic RNA can be, for example, *E. coli*,
20 *Salmonella*, *Shigella*, *Pseudomonas*, *Acinetobacter*, or other gram-negative bacteria. In some embodiments, the prokaryotic RNA in the adjuvant is total RNA extracted from one or more prokaryotic sources (e.g., more than one type of bacteria). In some embodiments, the prokaryotic RNA in the adjuvant is mRNA isolated from its prokaryotic source(s). In other embodiments, the prokaryotic RNA in the adjuvant is
25 transcribed or synthesized *in vitro*. RNA used in the adjuvant can be a mix of multiple RNA species, each with a different nucleotide sequence, or contains a single species of RNA molecules, each having or originating from the same nucleotide sequence.

[0052] The RNA in the adjuvant may be presented in a format that facilitates delivery into a cell by, e.g., phagocytosis or receptor-mediated endocytosis. For
30 example, the RNA may be encapsulated in liposomes, polylactide microspheres, or

poly(lactic-co-glycolic acid) microspheres, or linked or conjugated to the surface of a cargo (such as beads, and micro- or nano-particles). The RNA may also be co-administered with, or coupled to a molecule, such as an antibody or a specific ligand, that targets an endocytic receptor on the surface of antigen-presenting cells, such as

5 Fe-receptors or C-type-lectins (DC-SIGN, DEC-205), or to a protective antigen component of, e.g., anthrax toxin. The RNA may also be tagged (e.g., by incorporation of biotin molecules such as biotinylated nucleotides, or through Click-chemistry), and linked directly to an antigen-complex, a dead microbe, or a vaccine vector. The RNA in the adjuvant may also be complexed with other delivery agents,

10 including, without limitation, polyethylenimine, collagen derivatives, virosomes, SNALPs (stable nucleic acid lipid particles), ISCOMATRIX®, and polyethylene glycol (PEG). The RNA may also be delivered with other PAMPs such as CpG, lipopolysaccharide (LPS), flagellin, or MPLA.

[0053] In addition to prokaryotic RNA, the adjuvant of this invention can also

15 include a pharmaceutically acceptable excipient, and optionally other adjuvant ingredients. For example, the adjuvant of this invention may contain mineral oil, certain bacterial toxins, aluminium salts such as aluminium hydroxide and aluminium phosphate, squalene, virosomes, mineral oil in water emulsions (e.g., MF59, AS3, and montanide), CpG, LPS, MPLA, QS21 or AS02, flagellin, peptidoglycans, and/or

20 whole killed or otherwise inactivated bacterial pathogens. The adjuvant may also contain agents that help stabilize the immunogen and/or the RNA component, e.g., RNase inhibitors.

[0054] The present prokaryotic RNA adjuvants are different from existing adjuvants in that the former use a specific pathogen-associated molecular pattern (PAMP) that is

25 strictly associated with microbial viability. In contrast, currently available adjuvants contain PAMPs found in both live and dead microbes (such as peptidoglycans, CpG, flagellin, LPS, MPLA, AS04 (a mixture of MPL and aluminium salt), or virion particles), or even synthetic or chemical compounds not associated with infectious disease at all (such as alum, imiquimod, MF59, montanide, AS02 and QS21).

[0055] The vaccine compositions of this invention will provoke an immune response that closely mimics a productive infection tailored to clear infection and establish protective immunity. Thus, the prokaryotic RNA adjuvant of this invention is particularly useful when used in conjunction with a killed vaccine, because it can greatly enhance the immune response to the killed vaccine in a recipient, rendering the killed vaccine as effective as, if not more than, a live vaccine. The prokaryotic RNA adjuvant of this invention can also reduce the amount of immunogen, killed or live, required for vaccination, thereby increasing the safety and comfort of vaccination. Furthermore, prokaryotic RNA is safe to be used in vertebrate subjects because it is inert in vertebrates and does not cause any disease or undesirable conditions: once endocytosed, RNA is easily degradable by the host, and there is no hazard of genotoxicity because the prokaryotic origin and characteristics of the RNA prevent its integration or translation by host enzymes.

Vaccine Compositions

[0056] A vaccine composition of the present invention contains a target immunogen, the RNA adjuvant of this invention, and a pharmaceutically acceptable carrier such as saline. The target immunogen and the RNA adjuvant can be packaged separately and administered simultaneously, or they can be pre-mixed during manufacture of the vaccine composition. The vaccine composition may additionally contain other adjuvants such as mineral oil, certain bacterial toxins, aluminium salts, squalene, virosomes, mineral oil in water emulsions (e.g., MF59, MF50, AS3, and montanide), LPS, CpG, R848, MPLA, flagellin, peptidoglycans, saponin-based adjuvants (e.g., QS21), combination adjuvants (e.g., AS02 and AS04), and/or whole killed or otherwise inactivated bacterial pathogens and virion particles. An exemplary adjuvant combination is prokaryotic mRNA and MPL. The vaccine composition may additionally contain RNA stabilizers, other preservatives, mineral oils for prolonged half life and release, carrier molecules like antibodies, biodegradable particles, and encapsulating agents such as liposomes. Subjects that can be vaccinated by the vaccine compositions of this invention include, without limitations, humans, pets (e.g., dogs and cats), and livestock (e.g., cattle, horses, sheep, goats, swine, and chickens).

- [0057] The present invention provides vaccine compositions for infectious diseases such as those caused by bacteria and viruses. In some embodiments, the vaccine compositions comprise nonviable immunogens, e.g., pathogens that have been inactivated (e.g., killed by heat or other means) such that they cannot grow, spread, and cause disease in the vaccinated subject. The immunogens can be microbes such as bacteria that cause the particular disease for which the vaccine is intended. The immunogens may be viruses, parasites and fungi. The immunogens can be inactivated by, *inter alia*, heat, UV (e.g., long wavelength UV), beta- or gamma-radiation, ethanol, fixation (e.g., by the fixative paraformaldehyde), and/or psoralen.
- 5 [0058] The immunogens can be, for example, exogenous pathogens such as those from the genera *Escherichia*, *Streptococcus*, *Staphylococcus*, *Clostridium*, *Campylobacter*, *Enterococcus*, *Helicobacter*, *Moraxella*, *Acinetobacter* or obligate or facultative intracellular pathogens such as those from the genera *Acinetobacter*, *Shigella*, *Salmonella*, *Listeria*, *Legionella*, *Klebsiella*, *Pseudomonas*, *Brucella*, *Haemophilus*, *Bordetella*, *Borrelia*, *Bacteroides*, *Bacillus*, *Chlamydia*, *Neisseria*, *Francisella*, *Yersinia*, *Vibrio*, *Mycobacterium*, *Mycoplasma*, *Corynebacterium*, and *Rickettsia*.
- 15 [0059] In some embodiments, the vaccine compositions comprise a tumor antigen and an adjuvant comprising prokaryotic mRNA. In some embodiments, the vaccine compositions comprise an immunogenic peptide of microbial or mammalian origin and an adjuvant comprising prokaryotic mRNA. An immunogenic peptide is a peptide that produces an immunogenic response. Immunogenic peptides of microbial origin can be peptides that are isolated from a microbe, e.g., a bacterium, virus, fungus, protist, or protozoan. In some embodiments, the microbe can be a pathogen, such as an exogenous pathogen. Exemplary exogenous pathogens are described above.
- 20 Immunogenic peptides of mammalian origin can be peptides that are isolated from a mammal or a mammalian cell. In some embodiments, a peptide of mammalian origin can be a recombinant protein that naturally occurs in mammals. For example, the mammal can be a human, primate, mouse, rat, dog, cat, pig, cow, or horse.
- 25

[0060] The vaccine compositions of this invention will help combat various infectious diseases that have caused significant health problems worldwide. For example, Legionellosis (Legionnaire's disease, caused by *Legionella*), tuberculosis (caused by *Mycobacteria*), shigellosis (caused by *Shigella*), and *Clostridium difficile*-associated colitis represent some of the most dangerous infectious diseases worldwide, with high morbidity and mortality rates, and rising prevalence. They cause huge costs to the public health system. Yet no efficient vaccines are available to date for these diseases. Vaccine compositions comprising dead microbes and the RNA adjuvants of the invention will be effective in treating such diseases. Likewise, nosocomial infections with multidrug resistant strains of *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Moraxella*, or *Escherichia coli* represent a growing problem in hospitals worldwide. Prophylactic vaccination of risk patients (immunocompromised and elderly patients) using the vaccines of this invention can significantly lower complications and mortality, as well as reducing the need for expensive reserve antibiotics.

[0061] This invention also provides vaccine compositions for preventing or treating conditions other than infectious diseases, e.g., cancers, and immune disorders such as allergies and autoimmune diseases. In some embodiments, the immunogens are tumor cells that are inactivated so that they are not viable in the recipient. In other embodiments, the immunogens are autologous or allogeneic cells engineered *ex vivo* to express a tumor antigen; in this case, the immunogens need not be rendered nonviable. The prokaryotic RNA adjuvant can potentiate the immune response to these immunogens. Such vaccine compositions can be used to prevent cancer in a subject that is at risk of developing cancer (e.g., due to genetic predisposition or exposure to carcinogens) or to treat cancer in a subject. The cancer can be, e.g., cancer of the blood or cancer of solid tissues, such as leukemia, lymphoma, thymoma, skin cancer (e.g., melanoma), throat or neck cancer, thyroid cancer, gastrointestinal cancers (e.g., esophageal, gastric, intestinal, colonic, rectal, and anal cancers), liver cancer (hepatocellular carcinoma or cholangio-carcinoma), pancreatic cancer, renal cancer, adrenocortical carcinoma, urinary tract cancer (e.g., bladder cancer), prostate

cancer, testicular cancer, breast cancer, lung cancer (e.g., non-small cell lung cancer), mesothelioma, ovarian cancer, cervical cancer, vaginal cancer, brain cancer, retinoblastoma, sarcomas (e.g., Ewing's sarcomas), glioma, etc. In some embodiments, the prokaryotic RNA can be introduced into the tumor immunogen cells (e.g., by transfection, electroporation, and nucleofection) for delivery.

[0062] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art. Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. The materials, methods, and examples are illustrative only and not intended to be limiting.

20

EXAMPLES

[0063] The following examples describe our studies that show that the mammalian innate immune system can directly sense microbial viability through detection of a special class of viability-associated PAMPs (vita-PAMPs). These examples are meant to illustrate the methods and materials of the present invention. Suitable modifications and adaptations of the described conditions and parameters normally encountered in the art that are obvious to those skilled in the art are within the spirit and scope of the present invention.

[0064] In the following examples, we identified prokaryotic messenger RNA (mRNA) as a vita-PAMP present only in viable bacteria. Recognition of vita-PAMPs

30

elicits a unique innate response and a robust adaptive antibody response. Notably, the innate response evoked by viability and prokaryotic mRNA had previously been considered to be reserved for pathogenic bacteria (Sutterwala *et al.*, *J. Leukocyte Biol.* 82: 259-264 (2007)), but we show that even non-pathogenic bacteria in sterile tissues can trigger similar responses, provided that they are alive. Thus, the immune system actively gauges the infectious risk by scouring PAMPs for signatures of microbial life and thus infectivity. Detection of vita-PAMPs triggers an alert mode not warranted for dead bacteria. Vaccine formulations that incorporate vita-PAMPs can thus combine the superior protection of live vaccines with the safety of dead vaccines.

10 **Methods summary**

[0065] Cells were infected with *E. coli* DH5 α *ThyA*⁻ at MOI of 20 for 24 h unless stated otherwise. Supernatants were assayed for cytokines by ELISA. Genome wide transcriptional analysis of murine bone-marrow-derived macrophages (BMM) at 0, 1, 3 and 6 h post infection was carried out on Affymetrix GeneChip Mouse Gene 1.1 ST 24-array plates. Phagosomal leakage in BMMs was detected by measuring Fdx release using a modified method previously described (Davis *et al.*, *J Leukoc Biol* 88: 813-822 (2010)). In brief, BMMs were treated with *ThyA*⁻ *E. coli* in the presence of 0.167 mg/ml Fdx and imaged with excitation at 440nm (pH insensitive) and 485nm (pH sensitive). Fluorescence intensity ratios at 485nm/440nm were converted into pH maps and % Fdx release calculated (total intensity of pixels containing released Fdx/total Fdx intensity). Bacterial RNA was extracted from *E. coli* using the e.z.n.a RNA kit (Omega) and *in vitro* transcription of bacterial genes carried out using the MEGAscript kit (Ambion) followed by DNase digestion and RNA purification using MEGAclear kit (Ambion). RNA polyadenylation was performed with the poly(A)-tailing kit (Ambion). Vaccinations were performed as a prime-boost regimen (see full Methods). C57BL/6J and *P2rx7*^{-/-} mice were purchased from the Jackson Laboratory. *MyD88*^{-/-} and *Trif*^{-/-} mice were provided by S. Akira, *Myd88*^{-/-} $\times$ *Trif*^{-/-} by R. Medzhitov, *Nlrp3*^{-/-}, *Asc*^{-/-} and *Nlrc4*^{-/-} by Millenium, and *Caspase-1*^{-/-} by R. Flavell. Animal care and experimentation were performed in accordance with approved MSSM Institutional Animal Care and Use Committee protocols.

Cells

[0066] Bone marrow (BM)-derived dendritic cell (DC) cultures were grown as previously described (Torchinsky *et al.*, *Nature* 458: 78-82 (2009)) in RPMI 1640 supplemented with GM-CSF and 5% fetal bovine serum (FBS), plus 100 µg/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 10 mM HEPES, 1 nM sodium pyruvate, 1% MEM non-essential amino acids, and 2.5 µM β-mercaptoethanol (all SIGMA). Semi-adherent cells were harvested on ice on day 5 and re-plated immediately in fresh RPMI 1640 medium containing 10% FBS at 1×10^6 cells/well in 24-well tissue culture-treated plates. Stimuli were added immediately after re-plating in the same medium and the cells were centrifuged for 2' at 2000 rpm. Murine macrophages were derived from the BM (BMM) of either C57BL/6J, *Myd88*^{-/-}, *Trif*^{-/-}, *Trif*^{-/-} × *Myd88*^{-/-}, *Nlrp3*^{-/-}, *Asc*^{-/-} or *Casp1*^{-/-} mice, as described previously (Blander *et al.*, *Science* 304: 1014-1018 (2004)), in RPMI 1640 supplemented with M-CSF and 10% FBS, plus 100 µg/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES and 1 nM sodium pyruvate (all SIGMA). For some experiments macrophages were derived from BM of *Irf3*^{-/-} or *P2rx7*^{-/-} mice. Peritoneal macrophages were harvested 72h after intra-peritoneal injection of 1 ml thioglycollate (BD Bioscience), grown overnight in RPMI 1640 medium supplemented with 10% FBS and 100 µg/ml penicillin and 100 µg/ml streptomycin, hereafter referred to as "complete medium." Mouse embryonic fibroblasts (MEFs) deficient for RIG-I (*RIG-I*^{-/-}) were kindly provided by A. Ting with permission from S. Akira, and grown in DMEM medium containing 10% FBS and 100 µg/ml penicillin, 100 µg/ml streptomycin.

Mice

[0067] C57BL/6J and *P2rx7*^{-/-} mice were purchased from Jackson Laboratories. *Myd88*^{-/-} and *Trif*^{-/-} mice were originally provided by S. Akira, *Myd88*^{-/-} and *Trif*^{-/-} mice were interbred to homozygosity to generate *Trif* × *Myd88*^{-/-} mice, and were provided by R. Medzhitov. *Nlrp3*^{-/-}, *Asc*^{-/-} or *Casp1*^{-/-} bone marrow was provided by B. Ryffel and mice for *in vivo* studies were acquired from R. Flavell (through Millenium) and have been described previously (Sutterwala *et al.*, *Immunity* 24: 317-327 (2006); Kuida *et al.*, *Science* 267:

2000-2003 (1995)). *Irf3*^{-/-} mice were provided by C.B. Lopez and were previously described (Sato *et al.*, *Immunity* 13: 539-548 (2000)). We used 8-10 week old animals for all experiments. All experiments were approved by the institutional ethics committee and carried out in agreement with the “Guide for the Care and Use of Laboratory Animals” (NIH publication 86-23, revised 1985).

Bacteria

[0068] *E. coli* K12, strain DH5 α cells were purchased from Invitrogen. Naturally occurring Thymidine auxotrophs (*ThyA*⁻) were selected on Luria-Bertani (LB) agar plates containing 50 μ g/ml trimethoprim and 500 μ g/ml thymidine (both SIGMA).

10 Auxotrophy was confirmed by inoculation and overnight culture of single colonies in LB medium. *ThyA*⁻ *E. coli* cells grew only in the presence of thymidine and were resistant to trimethoprim. For phagocytosis experiments, *ThyA*⁻ *E. coli* cells were grown to mid-log phase, washed 3 times in phosphate buffered saline (PBS) to remove thymidine and LB salts prior to addition to cells. For heat killing, *ThyA*⁻ *E. coli* cells

15 were grown to log phase, washed and resuspended in PBS at an OD600 of 0.6, and subsequently incubated at 60°C for 60 minutes. *ThyA*⁻ heat killed (HK) *E. coli* cells were stored up to 18 hours at 4°C or used immediately after cooling. Efficient killing was confirmed by overnight plating on thymidine/trimethoprim supplemented LB-agar plates. For gentamicin killing, *ThyA*⁻ *E. coli* cells were grown to mid-log phase,

20 washed and resuspended in LB medium containing thymidine, trimethoprim and 50 μ g/ml gentamicin sulfate and incubated in a shaking incubator at 37°C overnight. Ethanol killing was carried out by resuspending log phase *ThyA*⁻ *E. coli* in 70% Ethanol for 10 minutes, followed by extensive washing in PBS. For UV killing, log phase *ThyA*⁻ *E. coli* cells were resuspended in PBS at an OD600 of 0.6, UV-irradiated

25 with 1000 mJ/cm² in a Petri dish followed by washing with PBS. Paraformaldehyde (PFA) fixation was performed by resuspending log phase *ThyA*⁻ *E. coli* in 4% PFA in PBS for 10 minutes followed by extensive washing and resuspension in PBS. *Shigella flexneri* virulence plasmid-cured strain BS103 was kindly provided by M.B. Goldberg. Wing *et al.*, *J Bacteriol* 186: 699-705 (2004); Maurell *et al.*, *Infect Immun* 49: 164-171

30 (1985). *ThyA*⁻ *S. flexneri* cells were selected similarly to *E. coli ThyA*⁻. D.M. Monack

kindly provided *Salmonella typhimurium*, strain SL1344 Δ *Spi1* Δ *Spi2*, lacking the *Salmonella* pathogenicity island SPI-1 and SPI-2 Type-III secretion systems (Haraga *et al.*, *Nat Rev Microbiol* 6: 53-66 (2008)). SL1344 Δ *Spi1* Δ *Spi2* was grown in LB medium containing 25 μ g/ml kanamycin and 12 μ g/ml tetracycline. *Listeria*

- 5 *monocytogenes* Δ *Hly* Δ *fliC* lacking listeriolysin O (LLO) and flagellin expression were kindly provided by D. Portnoy (Schnupf *et al.*, *Microbes Infect* 9: 1176-1187 (2007)).

Treatment of macrophages and dendritic cells with viable and killed bacteria

[0069] Macrophages were detached and re-plated 4 hours prior to the experiment. BMDC were re-plated immediately before addition of bacteria or soluble ligands.

- 10 Unless stated otherwise, bacteria were used at a multiplicity of infection (MOI) of 20. All experiments were carried out in antibiotic-free “complete medium.” One hour after addition of bacteria, penicillin (100 μ g/ml) and streptomycin (100 μ g/ml) were added to the medium in order to kill any remaining extracellular bacteria. Alternatively, gentamicin sulfate (50 μ g/ml) was used. We also compared this
- 15 approach to washing the cells and replacing the antibiotic-free medium with penicillin/streptomycin containing medium after one hour and found no differences with regards to the cellular responses measured. Supernatants were collected 24 hours after addition of the bacteria unless stated otherwise in the figure legends.

Cytokine Enzyme-linked immunoabsorbent assays (ELISA)

- 20 [0070] Supernatants from cultured BMM or BMDC were collected at 24 hours after stimulation or at the times indicated. ELISA antibody (Ab) pairs used for IL-6, IL-1 β and TNF- α were as listed below. All ELISA Abs were used at 2 μ g/ml capture and 0.5 μ g/ml detection, with the exception of IL-6 capture, which was used at 1 μ g/ml. Detection antibodies were biotinylated and labeled by streptavidin-conjugated
- 25 horseradish peroxidase (HRP), and visualized by addition of *o*-phenylenediamine dihydrochloride (SIGMA) (from tablets) or 3,3', 5,5'-tetramethylbenzidine solution (TMB, KPL). Color development was stopped with 3 M H₂SO₄ or TMB-Stop Solution (KPL), respectively. Recombinant cytokines served as standards and were purchased from Peprotech. Absorbances at 492 or 450 nm were measured,

respectively, on a tunable microplate reader (VersaMax, Molecular Devices).

Cytokine supernatant concentrations were calculated by extrapolating absorbance values from standard curves where known concentrations were plotted against absorbance using SoftMax Pro 5 software. Capture/detection Ab pairs were as

- 5 follows: IL-6, MP5-20F3/MP5-32C11 (BDPharmingen); IL-1 β , B12/rabbit polyclonal Ab (eBioscience); TNF- α , TN3-19/rabbit polyclonal Ab (eBioscience). IFN- β production was measured from supernatants using the VeriKine™ Mouse IFN-Beta ELISA Kit (PBL Interferon source) following manufacturer's instructions.

Anti-*E. coli* antibody ELISA

- 10 [0071] 96-well microtiter plates were coated overnight with *E. coli* lysates (3 μ g/ml) that we generated from log-phase cultures of *ThyA⁻ E. coli*. Serum samples from immunized mice were serially diluted (12 dilutions) and incubated in the pre-coated plates for 12 hours at 4°C followed by washing and incubation with rabbit anti-mouse isotype specific Ig-HRP (Southern Biotech) for 1 hour. Bound rabbit anti-mouse Ig-
15 HRP was visualized by addition of *o*-phenylenediamine dihydrochloride (SIGMA) from tablets, and the anti-*E. coli* antibody titers for each mouse were determined by absorbance readings at 490 nm.

Measurement of inflammatory cell death

- [0072] Cell death of macrophages or BMDC was measured using the Cytotox96
20 cytotoxicity assay (Promega) following manufacturer's instructions. The assay measures release of lactate dehydrogenase (LDH) into the supernatant calculated as percent of total LDH content, measured from cellular lysates (100%). LDH released by unstimulated cells was used for background correction.

Flow cytometric assessment of cell death

- 25 [0073] Cells were stimulated overnight, stained for Annexin V / 7AAD using the Annexin V-PE / 7AAD Apoptosis Detection kit (BD Pharmingen), and analyzed by flow cytometry (FACSCalibur, BD).

Flow cytometric measurement of reactive oxygen species (ROS)-production

- [0074] BMMs were loaded with the ROS indicator dye H2DCFDA (Molecular
30 Probes/Invitrogen, 10 mM in PBS) for 30 min followed by a recovery time of 30 min

in fresh pre-warmed “complete medium.” BMMs were then stimulated with viable or HK *E. coli* for 60 min, washed and analyzed by flow cytometry (FACSCalibur, BD).

Western Blots

[0075] For detection of Caspase-1, protein extracts were separated on 4-12% SDS-gradient gels (Invitrogen). For detection of all other proteins, samples were run on 5 10% SDS-polyacrylamide gels. Proteins were transferred to PVDF membranes (Millipore). Membranes were blocked with 5% milk in PBS and probed with the following Abs: Caspase-1 p10 (M-20) / rabbit polyclonal Ab, I κ B- α (C-21) / rabbit polyclonal Ab (both from Santa Cruz Biotechnologies), Phospho-IRF3 (Ser396) / 10 rabbit polyclonal Ab, IRF3 / rabbit polyclonal Ab, Phospho-p38 MAPK (Thr180/Tyr182) / rabbit polyclonal Ab, p38 MAPK / rabbit polyclonal Ab (all from Cell Signalling Technology), α -tubulin (DM1A) / rabbit monoclonal Ab (Novus Biologicals).

Real time PCR

15 [0076] Total RNA was isolated from macrophages using the RNeasy kit (QIAGEN). Contaminating genomic DNA was removed by DNase digestion (DNase I, Promega). Reverse transcription was performed using Superscript III (Invitrogen) and cDNA was used for subsequent real time PCR reactions. Quantitative real-time RT-PCR was conducted on an ABI Prism 7900 instrument using the MaximaTM SYBR green qPCR 20 Master Mix (Fermentas) with the following primer pairs. β -Actin: FW 5'-GAAGTCCCTCACCTCCCAA-3' (SEQ ID NO:1), RV 5'-GGCATGGACGCGACCA-3' (SEQ ID NO:2); *Il1b*: FW 5'-AAAGACGGCACACCCACCCTGC-3' (SEQ ID NO:3), RV 5'-TGTCCTGACCACTGTTGTTTCCCAG-3' (SEQ ID NO:4); *Ifnb*: FW 5'-GCACTGGGTGGAAT 3' (SEQ ID NO:5), RV 5'-TTCTGAGGCATCAA 3' (SEQ ID NO:6); *Nlrp3*: FW 5'-CGAGACCTCTGGGAAAAAGCT 3' (SEQ ID NO:7), RV 5'-GCATACCATAGAGGAATGTGATGTACA 3' (SEQ ID NO:8). All reactions were performed in duplicates and the samples were normalized to β -actin. “Fold inductions” were calculated using the $\Delta\Delta C^t$ method relative to unstimulated BMMs.

Transcriptome analysis

- [0077] BMMs derived from wild type (*wt*) or *Trif*^{-/-} mice were stimulated with viable *E. coli* for 0, 1, 3 or 6 hours and total RNA was extracted using the RNeasy kit (QIAGEN). RNA from three independent experiments was used for transcriptional analysis. RNA integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands) with 6000 Nano Chips. RNA was judged as suitable only if samples showed intact bands of 18S and 28S ribosomal RNA subunits, displayed no chromosomal peaks or RNA degradation products, and had a RNA integrity number (RIN) above 8.0.
- [0078] One hundred nanograms of RNA were used for whole transcript cDNA synthesis with the Ambion WT expression kit (Applied Biosystems, Nieuwekerk a/d IJssel, The Netherlands). Hybridization, washing and scanning of an Affymetrix GeneChip Mouse Gene 1.1 ST 24-array plate was carried out according to standard Affymetrix protocols on a GeneTitan instrument (Affymetrix, Santa Clara, CA).
- [0079] Packages from the Bioconductor project, integrated in an in-house developed management and analysis database for microarray experiments, were used for analysis of the scanned arrays (Gentleman *et al.*, *Genome Biol* 5, R80 (2004)). Arrays were normalized using the Robust Multi-array Average method (Bolstad *et al.*, *Bioinformatics* 19: 185-193 (2003); Irizarry *et al.*, *Nucleic acids research* 31: e15 (2003)). Probe sets were defined according to Dai *et al.*, *Nucleic acids research* 33: e175 (2005). With this method probes are assigned to unique gene identifiers, in this case Entrez IDs. The probes on the Gene 1.1 ST arrays represent 19,807 genes that have at least 10 probes per identifier. For the analysis, only genes that had an intensity value of > 20 on at least two arrays were taken into account. In addition, the interquartile range of log₂ intensities had to be at least 0.25. These criteria were met by 9,921 genes. Changes in gene expression are represented as signal log ratios between treatment and control. Multiple Experiment Viewer software (MeV 4.6.1) was used to create heatmaps (Saeed *et al.* *Biotechniques* 34, 374-378 (2003); Saeed, A.I., *et al.* *Methods Enzymol* 411, 134-193 (2006)). Genes were clustered by average linkage hierarchical clustering using Pearson correlation. Significantly regulated

genes were identified by Intensity-based moderated t-statistics (Sartor *et al.*, *BMC Bioinformatics* 7: 538 (2006)). Obtained *p*-values were corrected for multiple testing by a false discovery rate method (Storey *et al.*, *Proc Natl Acad Sci USA* 100: 9440-9445 (2003)).

- 5 **[0080]** IFN-regulated genes were identified using the Interferome database (interferome.org) (Samarajiwa *et al.*, *Nucleic acids research* 37: D852-857 (2009)) and grouped in a heat map. Rel/NF- κ B target genes were identified using another online database (bioinfo.lifl.fr/NF-KB/) which compiles Rel/NF- κ B target genes identified by various groups (Pahl, *Oncogene* 18: 6853-6866 (1999)). Inflammasome-related genes were compiled based on the current literature (Schroder *et al.*, *Cell* 140: 821-832 (2010); Coll *et al.*, *J Innate Immun* 2: 406-421 (2010)).

Measuring release from bacterial phagosomes

- [0081]** Measurement of fluorescein-dextran (Fdx) release from macrophage phagosomes was performed using a modified method previously described (Davis *et al.*, *J Leukoc Biol* 88: 813-822 (2010)). BMMs were plated onto Mat-tek coverslip dishes (MatTek Corp. Ashland, MA, USA) and incubated overnight. BMMs were stimulated with viable or gentamicin-killed red fluorescent protein (RFP)-expressing *ThyA⁻ E. coli* in the presence of 0.167 mg/mL Fdx in 200 μ L of medium. After 120 minutes of co-culture, additional Fdx and gentamicin containing medium was added to the coverslip dishes to prevent drying and to prevent bacterial overgrowth. Cells were imaged after 2, 4 and 8 hours to measure release of Fdx. Microscopic imaging was performed on an IX70 inverted microscope (Olympus, Center Valley, PA, USA) equipped with an X-cite 120 metal halide light source (EXFO, Mississauga, ON, Canada) and excitation and emission filter wheels. Phase contrast and two fluorescent images were acquired for each field of cells. The fluorescent images used the same emission settings, but used different excitation band-pass filters. Fdx fluorescence intensity using an excitation filter centred at 440 nm is relatively insensitive to pH, while fluorescence intensity using an excitation filter centered at 485 is very sensitive to pH. The ratio of fluorescence intensity at 485 nm divided by 440 nm was converted to into pH maps using calibration curves generated by imaging BMM with Fdx

containing compartments at a series of fixed pH conditions. As described previously (Davis *et al.*, *J Leukoc Biol* 88: 813-822 (2010)), pixels with pH above 5.5 were designated as representing Fdx which has been released from endo-lysosomal compartments. Percent of Fdx release was calculated by dividing the total intensity of pixels containing released Fdx by the total Fdx intensity for each cell.

Infections and vaccinations

[0082] For measuring systemic cytokine levels, C57BL/6J *wt*, *Trif*^{-/-}, *Asc*^{-/-} or *Nlrp3*^{-/-} mice were injected with 1x10⁹ viable or 5x10⁹ HK *ThyA*⁻ *E. coli*, respectively. Blood samples were drawn 6 hours post infection, and cytokine concentrations were measured by ELISA. For determination of bacterial clearance, we infected mice with 5x10⁷ viable replication-sufficient *E. coli* by intraperitoneal injection. Mice were monitored daily and moribund animals were sacrificed according to humane criteria established and approved by our institutional IACUC committee. After 60 hours, animals were euthanized and the spleens were explanted, homogenized, serially diluted and plated on LB-agar plates overnight followed by colony forming units (cfu) counting.

[0083] For vaccinations, we followed a prime-boost regimen as shown in the schematic in Figure 28 that was adopted from a previous study (Lim *et al.*, *Journal of Immune Based Therapies and Vaccines* 4: 5 (2006)). In brief, mice received an initial vaccination intraperitoneally with 5x10⁷ cfu of viable or HK *ThyA*⁻ *E. coli* or a combination of 5x10⁷ cfu HK *ThyA*⁻ *E. coli* and 30 µg of purified *E. coli* total RNA, followed by two boosts (5x10⁶ cfu) after 10 and 20 days. Polyclonal class-specific anti-*E. coli* antibody production was measured in the serum after 25 days by ELISA.

Bacterial RNA

[0084] Total bacterial RNA was isolated from *ThyA*⁻ *E. coli* using the e.z.n.a. Bacterial RNA Kit (Omega Bio-Tek), following the manufacturer's instructions. Contaminating DNA was removed by DNase digestion (TURBO DNase, Ambion/Applied Biosystems). Alternatively, total purified *E. coli* (DH5α) RNA was purchased from Ambion/Applied Biosystems, and similar results were obtained. Fractionation of bacterial RNA species was performed as follows. First, ribosomal

16S and 23S RNA (rRNA) was removed by a magnetic bead based capture hybridization approach using the MICROBExpress™ kit (Ambion/Applied Biosystems). The enriched RNA was then separated into messenger RNA (mRNA) and small RNA (sRNA, including 5S rRNA) using the MEGAClear™ kit (Ambion/Applied Biosystems). All separated RNA fractions were precipitated with ammonium acetate and resuspended in nuclease free water. RNA concentration and purity were determined by measuring the absorbance at 260/280 and 260/230 nm. RNA preparations were further visualized by 1% agarose gel electrophoresis.

In vitro RNA transcription

10 **[0085]** The *E. coli* Gro-operon encoding the bacterial chaperonins GroEL and GroES, the GTPase Era-operon or the DNA-polymerase-III-operon were PCR amplified from genomic DNA isolated from *ThyA⁻ E. coli* using primer pairs containing a T7 promotor sequence (T7) in either the FW or both FW and RV primer. The following primers were used.

15 Gro-FWT7: 5'-TAATACGACTCACTATAGGGCACCAGCCGGGAAACCACG-3' (SEQ ID NO:9);
 Gro-RVT7: 5'-TAATACGACTCACTATAGGAAAAGAAAAACCCCCAGACAT-3' (SEQ ID NO:10);
 Gro-RV: 5'-AGATGACCAAAGAAAAACCCCCAGACATT-3' (SEQ ID NO:11);
 20 Era-FWT7: 5'-TAATACGACTCACTATAGGGCATATGAGCATCGATAAAAGTTAC-3' (SEQ ID NO:12);
 Era-RV: 5'-TTTAAAGATCGTCAACGTAACCGAG-3' (SEQ ID NO:13);
 DNApol-FWT7: 5'-TAATACGACTCACTATAGGGATGTCTGAACCACGTTTCGT-3' (SEQ ID NO:14); and
 25 DNApol-RV: 5'-AGTCAAACCTCCAGTTCCACCTGCTCCGAA-3' (SEQ ID NO:15).

[0086] PCR fragments were purified using Nucleospin Extract II PCR purification kit (Macherey-Nagel), and used as DNA templates for *in vitro* transcription. *In vitro* transcription was performed using MEGAscript kit T7 (Ambion/Applied Biosystems) following the manufacturer's instructions. DNA templates generated with Gro-FWT7 and Gro-RV primers only contained a T7 promotor site in the sense strand and yielded
 30 single-stranded RNA, whereas PCR templates generated with Gro-FWT7 and Gro-

RVT7 primers contained T7 promotor sequences in both strands, allowing transcription of two complementary strands, yielding double-stranded RNA. For generation of 5'-capped RNA, m7G(5')ppp(5')G cap analog (Ambion/Applied Biosystems) was included in the transcription reaction at a GTP:cap ratio of 1:4.

5 **RNA digestion, dephosphorylation and polyadenylation**

[0087] *In vitro* transcribed Gro RNA, total *E. coli* RNA or *E. coli* mRNA were digested using RNase I (Promega) and RNase III (Ambion/Applied Biosystems). To remove 5'-triphosphates, RNA dephosphorylation was performed by incubating 10 µg *in vitro* transcribed RNA or total *E. coli* RNA or 1 mg of *E. coli* mRNA with 30U of calf intestinal alkaline phosphatase (CIP, New England Biolabs) for 2 hours at 37°C, as described previously (Hornung *et al.*, *Science* 314: 994-997 (2006)).

Polyadenylation of *in vitro* transcribed and purified bacterial mRNA was performed using the poly(A) Tailing kit (Ambion) following the manufacturer's instructions.

10 **Transfection of macrophages and MEFs**

15 [0088] For direct cytosolic delivery of total purified *E. coli* RNA or *in vitro* transcribed Gro RNA, 5x10⁵ BMM or 2x10⁵ MEFs were transfected with 1 mg of RNA using 2 µl of Lipofectamine 2000 (Invitrogen) in 24- or 12-well plates, respectively.

20 **Soluble ligands, inhibitors and other reagents**

[0089] Lipopolysaccharide (LPS) was purchased from SIGMA (*E. coli* 055:B5, phenol extracted). Caspase inhibitors z-YVAD, z-IEDT, Q-VD-OPH (all SM Biochemicals) were used at 50 µM, and added 30' prior to stimulation of cells.

25 **Poly (I:C)**

[0090] Poly (I:C) was purchased from Invivogen. Poly(I:C) is composed of a strand of poly(I) annealed to a strand of poly(C). Poly(I:C) (HMW) with a high molecular weight has an average size of 1.5-8 kb. Poly(I:C) (LMW) with a low molecular weight has an average size of 0.2-1 kb.

30 **Statistical Analysis**

[0091] Statistical significances were tested by ANOVA Kruskal-Wallis test and Bonferroni-Dunn *post hoc* correction. Significances are represented in the figures as

follows: *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$. “n.s.,” not statistically significant; #, “Not detected.”

Experimental Results

[0092] We hypothesized that the innate immune system may sense the most
 5 fundamental characteristic of microbial infectivity, microbial viability itself, and
 activate a robust immune response regardless of the presence of more specialized
 factors that regulate microbial virulence (Vance, et al., *Cell Host Microbe* 6: 10-21
 (2009)). To study sensing of bacterial viability without compounding effects of
 replication or virulence factors, we used thymidine auxotrophs of non-pathogenic
 10 *Escherichia coli* K12, strain DH5 α (*ECThyA*⁻). Viable and heat-killed (HK) *ECThyA*⁻
 similarly activated nuclear factor- κ B (NF- κ B) and mitogen-activated protein kinase
 p38 (Fig. 7) in bone marrow-derived macrophages and elicited production of similar
 amounts of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- α) (Fig. 1a).
 However, viable *ECThyA*⁻ induced higher levels of IFN- β than HK *ECThyA*⁻ or
 15 lipopolysaccharide (LPS) (Fig. 1b), and only viable *ECThyA*⁻ induced IL-1 β secretion
 (Fig. 1c; Fig. 8). Pro-IL-1 β transcription was equally induced by both viable and HK
ECThyA⁻ (Fig. 1c), suggesting that viable bacteria specifically elicit cleavage of pro-
 IL-1 β . This process is catalyzed by caspase-1 in Nod-like receptor (NLR)-containing
 inflammasome complexes, assembly of which can be triggered by the activity of
 20 bacterial virulence factors (Mariathasan *et al.*, *Nat Rev Immunol* 7:31-40 (2007);
 Schroder *et al.*, *Cell* 140:821-832 (2010)). Notably, avirulent viable but not HK
ECThyA⁻ induced inflammasome activation and pro-caspase-1 cleavage (Fig. 1d).
 Finally, viable but not HK *ECThyA*⁻ induced caspase-1-dependent inflammatory cell
 death, termed pyroptosis (Mariathasan *et al.*, *Nat Rev Immunol* 7: 31-40 (2007);
 25 Schroder, *et al.*, *Cell* 140: 821-832 (2010)), resulting in release of lactate
 dehydrogenase (LDH) (Fig. 1e) and appearance of 7-amino-actinomycin D
 (7AAD)⁺ Annexin-V^{-low} cells (Fig. 1f). Similar responses were observed in peritoneal
 macrophages and both splenic and bone marrow-derived dendritic cells (Fig. 8b).
 Killing *ECThyA*⁻ by UV irradiation, antibiotics, or ethanol, also selectively abrogated

IL-1 β secretion and pyroptosis without affecting IL-6 production (Fig. 1g; Fig. 9), suggesting that a general determinant associated with bacterial viability is detected.

- [0093] To determine whether pathogenic bacteria can also activate the inflammasome in the absence of virulence factors, we studied attenuated strains of selected pathogens: *Shigella flexneri* virulence plasmid-cured strain BS103 (Wing *et al.*, *J Bacteriol* 186: 699-705 (2004)), *Salmonella typhimurium*, SL1344 Δ *Spi1* Δ *Spi2*, lacking the Salmonella pathogenicity islands SPI-1 and SPI-2 (Mariathasan *et al.*, *Nat Rev Immunol* 7: 31-40 (2007)), and *Listeria monocytogenes* Δ *Hly* Δ *fliC*, lacking listeriolysin O and flagellin (Mariathasan *et al.*, *Nat Rev Immunol* 7: 31-40 (2007)).
- These mutants induced IL-1 β production at levels comparable to those induced by *ECThyA*⁻ (Fig. 1h; Fig. 5), but lower and with slower kinetics than their pathogenic counterparts (Fig. 10; Fig. 5). IL-1 β production was abolished when these bacteria were killed, whereas IL-6 production was similar (Fig. 1h). Thus, immune cells detect universal characteristics of viability different from virulence factors.
- [0094] Caspase-1 activation, pyroptosis and IL-1 β production in response to *ECThyA*⁻ were abrogated in macrophages deficient for NLRP3 or for the inflammasome adaptor Apoptosis Speck protein with Caspase recruitment (ASC or PYCARD) (Schroder *et al.*, *Cell* 140: 821-832 (2010)) (Figs. 1i and 1j), while NLRC4 was dispensable (Fig. 11). Pyroptosis and IL-1 β production induced by viable *ECThyA*⁻ were abrogated in *Casp1*^{-/-} macrophages (Fig. 1j) and suppressed by inhibitors for caspase-1, but not caspase-8 (Fig. 12).

- [0095] Induction of IFN- β mRNA and protein by viable *ECThyA*⁻ required the Toll-like receptor (TLR) adaptor TRIF (Takeuchi *et al.*, *Cell* 140: 805-820 (2010)) (Figs. 2a,b) and downstream interferon regulatory factor-3 (IRF3) (Takeuchi *et al.*, *Cell* 140: 805-820 (2010)) (Fig. 13), but not MyD88, the main TLR adaptor (Takeuchi *et al.*, *Cell* 140: 805-820 (2010)) (Figs. 2a,b). In contrast, transcription of pro-IL-1 β was largely dependent on MyD88. Consequently, *Myd88*^{-/-} cells secreted no IL-1 β (Figs. 2c,d), whereas pyroptosis and caspase-1 cleavage were intact (Fig. 2e,f). Notably, while TRIF was dispensable for pro-IL-1 β transcription (Fig. 2c), *Trif*^{-/-} cells failed to

secrete IL-1 β (Fig. 2d), were protected from pyroptosis (Fig. 2e), and did not activate caspase-1 (Fig. 2f). These findings revealed an unexpected role for TRIF in NLRP3 inflammasome activation in response to viable *ECThyA*⁻. In contrast, pyroptosis induced by pathogenic *S. typhimurium* (Monroe *et al.*, *PLoS Pathog* 5: e1000665 (2009)), proceeded independently of TRIF (Fig. 14). Differential involvement of TRIF, together with differences in magnitude and kinetics of the response (Fig. 1h; Fig. 10), indicated that inflammasome activation in response to virulence factors occurs in a manner distinct from that to viability.

[0096] Genome-wide transcriptional analysis of wild type and *Trif*^{-/-} macrophages before and after phagocytosis of viable *ECThyA*⁻ showed differential regulation of several clusters of genes (Fig. 15) including IFN-regulated genes, as expected (Takeuchi *et al.*, *Cell* 140: 805-820 (2010)) (Figs. 2a and 2b; Fig. 16a), while most of Rel/NF- κ B target genes were comparable (Fig. 16b). *Nlrp3* expression was induced independently of TRIF (Figs. 2g and 2h) and negative regulators of inflammasome activity such as those encoded by *Mediterranean fever* (*Mefv*), *Nlrp10* and *Casp12* genes were also unchanged or expressed at higher levels in wild type macrophages (Fig. 2g), possibly due to negative feedback. Thus, the role of TRIF in inflammasome activation upon phagocytosis of viable *ECThyA*⁻ is not explained by transcriptional control of inflammasome components (so called priming (Schroder *et al.*, *Cell* 140: 821-832 (2010))). Furthermore, ATP and reactive oxygen species (ROS) (Schroder *et al.*, *Cell* 140: 821-832 (2010); Zhou *et al.*, *Nature* 469: 221-225 (2011)), known activators of the NLRP3 inflammasome, were not involved, as deficiency for P₂X₇R, required for ATP-mediated NLRP3 activation, did not affect pyroptosis or IL-1 β production (Figs. 17a and 17b), and ROS accumulated equally in response to viable and HK *ECThyA*⁻ independently of TRIF (Fig. 17c).

[0097] Injection of viable and HK *ECThyA*⁻ into mice induced similarly high serum levels of IL-6 (Fig. 2i). In contrast, circulating IL-1 β was detected only in mice infected with viable bacteria (Fig. 2i), while IFN- β levels were undetectable in all groups (not shown). Confirming our results *in vitro*, production of IL-1 β (but not IL-6) *in vivo* also required TRIF, ASC, and NLRP3 (Fig. 2i). Injection of non-pathogenic *S.*

typhimurium induced serum IL-1 β levels comparable to those elicited by *ECThyA*⁻, which similarly depended on TRIF (Fig. 18). Although pathogenic *S. typhimurium* elicited higher levels of serum IL-1 β than non-pathogenic *Salmonella*, this response was also severely reduced in *Trif*^{-/-} mice, suggesting a previously unappreciated role for TRIF in *Salmonella* infection (Fig. 18). Importantly, deficiency in TRIF, ASC and NLRP3 impaired bacterial clearance during systemic infection with replication sufficient non-pathogenic *E. coli* (Fig. 2j). This failure was more dramatic in *Trif*^{-/-} than in *Asc*^{-/-} or *Nlrp3*^{-/-} mice, possibly due to the central upstream role of TRIF in inflammasome activation and IFN- β production.

10 **[0098]** The ability to sense microbial viability through pathways downstream of pattern recognition receptors suggests the existence of vita-PAMPs; PAMPs associated with viable but not dead bacteria. In contrast to LPS and genomic DNA that remained constant after killing *ECThyA*⁻ with heat, total bacterial RNA was rapidly lost (Figs. 3a and 3b; Fig. 19). Total RNA content was also lost with antibiotic treatment, and little
15 ribosomal RNA (rRNA) remained after killing with UV and ethanol (Fig. 20). Only fixation with paraformaldehyde (PFA) efficiently killed the bacteria (not shown), but preserved total RNA content (Fig. 21a). Remarkably, unlike bacteria killed by other means, PFA-killed bacteria induced pyroptosis and IL-1 β to levels similar to those induced by viable bacteria (Fig. 21b). Thus, the presence or absence of RNA
20 correlated with the ability to activate pathways involved in sensing viability.

[0099] These results suggest that prokaryotic RNA represents a labile PAMP closely associated with bacterial viability, which might signify microbial life to the immune system. Indeed, addition of purified total bacterial RNA fully restored the ability of HK *ECThyA*⁻ to induce pyroptosis, IL-1 β and IFN- β production (Fig. 3c). These
25 responses were dependent on TRIF, NLRP3 and caspase-1, just as those elicited by viable bacteria (Fig. 3d compared to Figs. 1j and 2a-f). The NLRP3 inflammasome mediates recognition of viral RNA during Influenza A infection (Pang *et al.*, *Trends Immunol* 32: 34-41 (2011)). Our results suggest a more general role for NLRP3 in responses to RNAs of microbial origin. RNA can activate the NLRP3 inflammasome
30 when delivered into the cytosol (where NLRP3 resides) with transfection reagents

(Kanneganti *et al.*, *Nature* 440: 233-236 (2006)). In contrast, inflammasome activation by the combination of total bacterial RNA and dead *ECThyA*⁻ did not require RNA transfection (Figs. 3c and 3d). Administration of total *E. coli* RNA alone or in combination with LPS (to mimic an *E. coli*-derived PAMP+RNA) had little effect on NLRP3 inflammasome activation unless the RNA was delivered to the cytosol using Lipofectamine (Fig. 22) or in combination with ATP. Thus, phagocytosis of viable bacteria is a natural context of bacterial RNA-mediated NLRP3 inflammasome activation.

[0100] These findings raised the question as to how vita-PAMPs in phagolysosomes gain access to cytosolic receptors such as NLRP3 in the absence of invasion, auxiliary secretion systems or pore forming toxins. To address this question, we exploited the pH sensitive excitation spectrum of fluorescein: the acidic pH in phagolysosomes quenches fluorescence while release into the pH neutral cytosol allows a regain in fluorescence (Davis *et al.*, *J Leukoc Biol*: 88, 813-822 (2010)). Phagocytosis of avirulent *ECThyA*⁻ in the presence of fluorescein-conjugated dextran (Fdx), consistently induced low level release of Fdx into the cytosol of macrophages (Figs. 3e and 3f; Fig. 23). This indicates that phagosomes carrying *E. coli* exhibit intrinsic leakiness, a property previously described for particles such as beads and crystals that induce phagolysosomal destabilization (Davis *et al.*, *J Leukoc Biol* 88: 813-822 (2010); Hornung *et al.*, *Nat Immunol* 9: 847-856 (2008)). Interestingly, killed *E. coli* also induced Fdx release, although to a slightly lower extent than viable *E. coli* (Figs. 3e and 3f), demonstrating that phagosomal leakage occurs independently of bacterial viability. Therefore, RNA from viable bacteria could gain access to cytosolic receptors via intrinsic phagosomal leakage. These results may also explain the reported ability of phagosome-degraded mutants of *Listeria monocytogenes* or *Staphylococcus aureus* to induce a transcriptional response dependent on cytosolic NLRs (Herskovits *et al.*, *PLoS Pathog* 3: e51 (2007); Shimada *et al.*, *Cell Host Microbe* 7: 38-49 (2010)).

[0101] Digestion of total RNA from *E. coli* with exonuclease RNase I and double-stranded RNA (dsRNA)-specific endonuclease RNase III abrogated LDH and IL-1 β

release, while DNase treatment had no effect (Fig. 4a). Of *E. coli* RNA species, mRNA most potently induced pyroptosis as well as production of IL-1 β and IFN- β . Small RNA (sRNA) or the most abundant RNA, ribosomal RNA (rRNA), had little or no detectable effects (Fig. 4b; Fig. 24). *E. coli* rRNA undergoes extensive

5 modifications not found in mRNA (Piekna-Przybylska *et al.*, *Nucleic Acids Res* 36: D178-183 (2008)), which may underlie the differential activity of these RNA species. The relative amount of mRNA was <1% of the total RNA and accordingly, mRNA was approximately 100-fold more effective than total RNA (Figs. 3c, 4a and 4b, and 24).

10 **[0102]** *In vitro* transcribed single-stranded mRNA of the *E. coli* Gro-operon (Figs. 25a and 25b), which is strongly expressed upon phagocytosis of bacteria (Buchmeier *et al.*, *Science* 248: 730-732 (1990)), induced caspase-1 cleavage and subsequent pyroptosis and IL-1 β production when phagocytosed together with HK *ECThyA*⁻ (Figs. 4c and 4e; Fig. 6; Figs. 25c-e). The single-stranded Gro-mRNA sequence had a

15 predicted secondary structure with regions of high probability for base pairing (Fig. 4d), consistent with susceptibility of the stimulatory activity to RNase III treatment (Fig. 4a). Indeed, fully dsGro-mRNA (Fig. 25b) induced similar responses as single-stranded Gro-mRNA of the appropriate length (Fig. 4e; Fig. 25d). Other transcripts also induced such responses, showing that the immunostimulatory property is

20 independent of RNA sequence (Fig. 4f).

[0103] Eukaryotic RNA was unable to elicit the responses induced by *E. coli* mRNA (Fig. 4b; Fig. 6). Unlike eukaryotic mRNA, tri-phosphate moieties at the 5' end of bacterial mRNAs are not capped with 7-methyl-guanosine (7m⁷G) (Belasco, *Nat Rev Mol Cell Biol* 11: 467-478 (2010)), and might betray the prokaryotic origin of these

25 transcripts (Rehwinkel *et al.*, *Science* 327: 284-286 (2010)). However, neither treatment with calf intestinal phosphatase (CIP) nor capping affected the activity of Gro-mRNA during phagocytosis of HK *ECThyA*⁻ (Fig. 4g). The stimulatory activity of purified *E. coli* total RNA or mRNA was also unaltered by CIP treatment (Figs. 26a and 26b), arguing against a role for the RNA helicase retinoic acid inducible gene-I

30 (RIG-I), which can induce interferon and IL-1 β production, but requires 5'-

triphosphates for activation (Fig. 26c) (Rehwinkel *et al.*, *Science* 327: 284-286 (2010)), as well as the interferon inducible protein kinase PKR, which can be activated by 5'-triphosphate bearing RNAs of viral or bacterial origin (Nallagatla *et al.*, *RNA Biol* 5: 140-144 (2008)). Moreover, TRIF and NLRP3 are dispensable for RIG-I function, but required for the stimulatory activity of bacterial RNA (Figs. 2a, 2b, and 3d). Interestingly, RNA can induce RIG-I-dependent IFN- β during infection with an invasive intracellular bacterium (Monroe, K.M., McWhirter, S.M. & Vance, R.E. *PLoS Pathog* 5, e1000665 (2009)), suggesting that the nature of microbial pathogenesis and cellular context in which bacterial RNA is recognized may determine the choice of innate sensors engaged. In contrast to 5'-triphosphate removal, adding polyadenyl groups to the 3' end of Gro-mRNA or purified *E. coli* mRNA abrogated IL-1 β secretion and pyroptosis (Fig. 4g; Fig. 27). Similar results were obtained when we used primary human monocytes isolated from peripheral blood. Human monocytes produced IL-1 β only after stimulation with live *ECThyA*⁻, but not with HK *ECThyA*⁻ (unpublished data, not shown). In addition to *E. coli*, we also examined the responses to live and HK *Acinetobacter baumannii*, a pathogenic bacterium with low virulence in immunocompetent individuals, but high multi-drug resistance rates. Similar to *ECThyA*⁻, only live but not HK *Acinetobacter baumannii* induced IL-1 β release from human monocytes, whereas no differences were observed for IL-6 production (unpublished data, not shown). Stimulation of human peripheral blood mononuclear cells (PBMC), containing monocytes and lymphocytes, with live *ECThyA*⁻ induced the production of IgG and IgA, which was not observed upon stimulation with HK *ECThyA*⁻ (unpublished data, not shown). These results demonstrate the cross-species relevance of our findings and have direct implications for the use of vita-PAMPs such as bacterial RNA as potent new vaccine adjuvants in humans. It also follows that the absence of 3'-polyadenylation (Belasco, *Nat Rev Mol Cell Biol* 11: 467-478 (2010)) may allow specific detection of prokaryotic mRNA during infection. Additional features may distinguish self from microbial RNAs such as internal naturally occurring nucleoside modifications in eukaryotic RNA (Nallagatla, *supra*; Kariko *et al.*, *Immunity* 23: 165-175 (2005)).

[0104] To test the impact of vita-PAMPs on adaptive immunity, we immunized mice with either viable or dead *ECThyA*⁻, or a combination of dead *ECThyA*⁻ and purified total bacterial RNA (Fig. 28). While all three vaccines induced similar polyclonal anti-*E. coli* IgM responses, production of class-switched IgG subclasses was strongly enhanced in response to vaccination with viable compared to killed *E. coli* (Fig. 4h). Adding total bacterial RNA to killed *ECThyA*⁻ elevated IgG1, IgG2c, IgG2b and IgG3 antibody titers to or above the levels in mice immunized with viable *ECThyA*⁻. Thus, innate detection of bacterial viability leads to robust activation of a humoral adaptive response. These findings indicate that bacterial RNA can augment killed vaccines to perform as well as live ones.

[0105] To test whether synthetic RNA can be used to mimic the effects of prokaryotic RNA on the immune response, we treated BMDC with Poly (I:C), the synthetic analog of double-stranded RNA. We found that unlike bacterial RNA, neither the low molecular weight (LMW) poly(I:C) nor the high molecular weight (HMW) poly(I:C) was capable of inducing IL-1 β (Fig. 29a and Fig. 29b) or lactate dehydrogenase (LDH) release (Fig. 29b) from BMDC when combined with heat-killed *E. coli*. TNF- α production, which can be induced by both live and dead *E. coli*, was not affected by the addition of LMW and HMW forms of Poly(I:C) (Figs. 29a and b). The LMW and HMW forms alone induced neither IL-1 β nor TNF- α production (Figs. 29a and b). These results demonstrate that poly(I:C) may not fully recapitulate the responses induced by bacterial RNAs, and that features unique to bacterial RNAs that are not reproduced in the synthetic poly(I:C) molecule are particularly efficient at inducing these responses. Therefore, new synthetic RNAs that incorporate the key features described herein (e.g., a 3' stem loop structure) would be superior to poly(I:C) in serving as an adjuvant that replicates the protective immunity elicited by live vaccines.

[0106] Our findings reveal an inherent ability of the immune system to distinguish viable from dead microorganisms. The presence of live bacteria in sterile tissues, regardless of whether these (still) express virulence factors, poses an acute threat that must be dealt with by an aggressive immune response. Dead bacteria, on the other

hand, would signify a successful immune response that can now subside. Detection of vita-PAMPs within sterile tissues signifies microbial viability. Other vita-PAMPs may exist in the form of second messengers like cyclic di-adenosine or di-guanosine monophosphates (Vance, *et al.*, *Cell Host Microbe* 6: 10-21 (2009); Woodward *et al.*,
5 *Science* 328: 1703-1705 (2010)) or quorum-sensing molecules (Vance *et al.*, *Cell Host Microbe* 6: 10-21 (2009)). Given that bacteria tightly regulate their virulence via multiple mechanisms in response to different environmental signals and inside a host organism during infection (Gripenland *et al.*, *Nat Rev Microbiol* 8: 857-866 (2010); Raskin *et al.*, *Cell* 124: 703-714 (2006)), detection of invariant vita-PAMPs essential
10 to bacterial survival may be a non-redundant fail-safe strategy for host protection.

What is claimed is:

1. A vaccine composition comprising a nonviable immunogen and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA.
2. The composition of claim 1, wherein the immunogen is an extracellular pathogen.
3. The composition of claim 1, wherein the immunogen is an intracellular pathogen.
4. The composition of claim 1, wherein the immunogen is a bacterium.
5. The composition of claim 4, wherein the bacterium is of a genus selected from a group consisting of *Escherichia*, *Streptococcus*, *Staphylococcus*, *Clostridium*, *Campylobacter*, *Enterococcus*, *Helicobacter*, *Moraxella*, *Acinetobacter*, *Shigella*, *Salmonella*, *Listeria*, *Legionella*, *Klebsiella*, *Pseudomonas*, *Brucella*, *Haemophilus*, *Bordetella*, *Borrelia*, *Bacteroides*, *Bacillus*, *Chlamydia*, *Neisseria*, *Francisella*, *Yersinia*, *Vibrio*, *Mycobacterium*, *Mycoplasma*, *Corynebacterium*, and *Rickettsia*.
6. The composition of claim 1, wherein the prokaryotic mRNA is contained in the immunogen.
7. A vaccine composition comprising a tumor antigen and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA.
8. The composition of claim 7, wherein the tumor antigen is carried by a cell.
9. The composition of claim 8, wherein the prokaryotic mRNA is contained in the cell.
10. A vaccine composition comprising an immunogenic peptide of microbial or mammalian origin and an adjuvant, wherein said adjuvant comprises prokaryotic mRNA.
11. The composition of claim 10, wherein the immunogenic peptide is carried by a cell.
12. The composition of claim 11, wherein the prokaryotic mRNA is contained in the cell.
13. The composition of any one of claims 1-12, wherein the mRNA has a 3' stem-loop structure.

14. The composition of any one of claims 1-12, wherein the mRNA has no 5' tri-phosphate group.
15. The composition of any one of claims 1-12, wherein the mRNA has no 3' poly(A) tail.
16. The composition of any one of claims 1-12, wherein the mRNA contains intramolecular base-pairing and/or nucleotide modifications.
17. A method of eliciting an immune response in a subject, comprising administering to the subject the composition of any one of claims 1-16.
18. A method of increasing the immune response to a killed vaccine in a subject, comprising administering the killed vaccine to the subject with an adjuvant comprising prokaryotic mRNA.
19. The method of claim 17 or 18, wherein the subject is human.
20. The method of claim 17 or 18, wherein the immune response protects the subject from developing an infectious disease.
21. The method of claim 17 or 18, wherein the immune response protects the subject from developing a cancer, or treats a subject in need of cancer immunotherapy.
22. The method of claim 17 or 18, wherein the immune response comprises one or more of the following: IL-1 β production, IFN- β production, increased IgG isotype levels, increased primary and secondary T cell responses, and death of infected cells.
23. A method of inducing IFN- β or IL-1 β production in immune cells, comprising contacting the cells with the composition of any one of claims 1-16.
24. A method of preparing a vaccine composition, comprising mixing a target immunogen with prokaryotic mRNA.
25. An immunization kit, comprising a vaccine composition comprising a nonviable immunogen, and an adjuvant composition comprising prokaryotic mRNA.

26. An immunization kit, comprising a vaccine composition comprising a tumor antigen, and an adjuvant composition comprising prokaryotic mRNA.





FIG. 1







FIG. 2







FIG. 3





FIG. 3

**FIG. 3**




FIG. 3




FIG. 4




FIG. 4




FIG. 4




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10





FIG. 11

**FIG. 12**




FIG. 13





FIG. 14

**FIG. 15**




FIG. 15





FIG. 16



1961



FIG. 17




FIG. 17




FIG. 18




FIG. 19





FIG. 20

**FIG. 21**




FIG. 22




FIG. 23




FIG. 24




FIG. 24




FIG. 25







FIG. 25

**FIG. 26**

b**FIG. 26**




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 29